FORM PTO 1449	ATTY. DOCKET NO. 0257-0003	APPLICATION NO. 09/837,297
INFORMATION DISCLOSURE STATEMENT	APPLICANT(S) Lee et al	
	FILING DATE April 19, 2001	GROUP ~~1646~~ 1648

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
LM		5,981,274	11/9/99	Tyrrell et al	—	—	

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
							☐Yes ☐No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

LM			Anderson, W., *Human Gene Therapy*, Science, 256: 808-13 (1992)
			Ausubel, F. et al. eds. Current Protocols in Molecular Biology, Wiley and Sons, New York, Suppl. 48 (1995)
			Chaisomchit, S. et al., *Development of replicative and nonreplicative hepatitis B virus vectors*, Gene Therapy, 4: 1330-40 (1997)
			Chiang P. et al., *Characterization of a cis Element Required for Packaging and Replication of the Human Hepatitis B Virus*, Virology, 186: 701-11 (1992)
			Condreay, L. et al., *Replication of DHBV Genomes with Mutations at the Sites of Initiation of Minus- and Plus-Strand DNA Synthesis*, Virology, 188: 208-16 (1992)
			Crystal, R., *Transfer of Genes to Humans: Early Lessons and Obstacles to Success*, Science, 270: 404-10 (1995)
			Douglas, J. et al., *A system for the propagation of adenoviral vectors with genetically modified receptor specificities*, Nature Biotechnology, 17: 470-75 (1999)
			Friedman T., *The Origins, Evolution, and Directions of Human Gene Therapy*, The Development of Human Gene Therapy, Cold Spring Harbor Laboratory Press, NY, (1999)
			Galibert, F. et al., *Nucleotide sequence of the hepatitis B virus genome (subtype ayw) cloned in E. coli*, Nature, 28: 646-50 (1979)
			Ganem, D. et al., *Hepadnaviridae and Their Replication*, Fundamental Virology, 3rd ed., 1199-1233 (1996)
			Ganem, D. et al., *The Molecular Biology of The Hepatitis B Viruses*, Ann. Rev. Biochem., 56: 651-93 (1987)
			Havert, M. et al., *cis-Acting Sequences in Addition to Donor and Acceptor Sites Are Required for Template Switching during Synthesis of Plus-Strand DNA for Duck Hepatitis B Virus*, Journal of Virology, 71: 5336-44 (1997)
			Hirsh, R. et al., *cis-Acting Sequences Required for Encapsidation of Duck Hepatitis B Virus Pregenomic RNA*, Journal of Virology, 65: 3309-16 (1991)
			Ho, T., et al., *Effects of Genomic Length on Translocation of Hepatitis B Virus Polymerase-Linked Oligomer*, Journal of Virology, 74: 9010-18 (2000)
			Jeong, J. et al. *Evidence that the 5'-end Cap Structure Is Essential for Encapsidation of Hepatitis B Virus Pregenomic RNA*, Journal of Virology, 74: 5502-08 (2000)
			Junker-Niepmann, M. et al., *A short cis-acting sequence is required for hepatitis B virus pregenome encapsidation and sufficient for packaging of foreign RNA*, The EMBO Journal, 9: 3389-96 (1990)
			Loeb D. et al., *Mutations within DR2 Independently Reduced the Amount of both Minus- and Plus-Strand DNA Synthesized during Duck Hepatitis B Virus Replication*, Journal of Virology, 70: 8684-90 (1996)

EXAMINER LM	DATE CONSIDERED 11/24/04

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO 1449	ATTY. DOCKET NO. 0257-0003	APPLICATION NO. 09/837,297
INFORMATION DISCLOSURE STATEMENT	APPLICANT(S) Lee et al	
	FILING DATE April 19, 2001	GROUP ~~1646~~ 1648

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
							☐Yes ☐ No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

LO			Loeb D. et al., *Sequence Identity of the Terminal Redundancies on the Minus-Strand DNA Template Is Necessary but Not Sufficient for the Template Switch during Hepadnavirus Plus-Strand DNA Synthesis*, Journal of Virology, 71: 152-60 (1997)
			Loeb D. et al., *Sequence-independent RNA cleavages generate the primers for plus strand DNA synthesis is hepatitis B viruses: implications for other reverse transcribing elements*, The EMBO Journal, 10: 3533-540 (1991)
			Loeb D. et al., *Transfer of the Minus Strand of DNA during Hepadnavirus Replication Is Not Invariable but Prefers a Specific Location*, Journal of Virology, 69: 6886-891 (1995)
			Mulligan, R., *The Basic Science of Gene Therapy*, Science, 260: 926-32 (1993)
			Nassal, M. et al., *A Bulged Region of the Hepatitis B Virus RNA Encapsidation Signal Contains the Replication Origin for Discontinuous First-Strand DNA Synthesis*, Journal of Virology, 70: 2764-73 (1996)
			Nassal, M. et al., *Hepatitis B Virus Replication- an update*, Journal of Viral Hepatitis, 3: 217-26 (1996)
			Nassal, M. et al., *Translational Inactivation of RNA Function: Discrimination against a Subset of Genomic Transcripts during HBV Nucleocapsid Assembly*, Cell, 63: 1357-63 (1990)
			Pollack, J. et al., *Site Specific RNA Binding by a Hepatitis B Virus Reverse Transcriptase initiates Two Distinct Reactions: RNA Packaging and DNA Synthesis*, Journal of Virology, 68: 5579-87
			Protzer, U. et al., *Interferon gene transfer by a hepatitis B virus vector efficiently suppresses wild-type virus infection*, Proc. Natl. Acad. Sci., 96: 10818-23 (1999)
			Sambrook et al., *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Press 3rd ed, (2001)
			Seeger, C. et al., *Identification of a Signal Necessary for Initiation of Reverse Transcription of the Hepadnavirus Genome*, Journal of Virology, 65: 5190-95 (1991)
			Sells, M. et al., *Replicative Intermediates of Hepatitis B Virus in HepG2 Cells That Produce Infectious Virions*, Journal of Virology, 62: 2836-44 (1988)
			Shih, C. et al., *In vitro propagation of human hepatitis B virus in a rat hepatoma cell line*, Proc. Natl. Acad. Sci., 86: 6323-27 (1989)
			Staprans, S. et al., *Mutations Affecting Hepadnvirus Plus-Strand DNA Synthesis Dissociate Primer Cleavage from Translocation and Reveal the Origin of Linear Viral DNA*, Journal of Virology, 65: 1255-62 (1991)

EXAMINER LO	DATE CONSIDERED 11/24/04

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO 1449 INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 0257-0003	APPLICATION NO. 09/837,297
	APPLICANT(S) Lee et al	
	FILING DATE April 19, 2001	GROUP ~~1646~~ 1648

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
							☐Yes ☐ No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

LCO			Wang, G. et al., *Novel Mechanism for Reverse Transcription in Hepatitis B Virus*, Journal of Virology, 67: 6507-12 (1993)
			Wang, G. et al., *The Reverse Transcriptase of Hepatitis B Virus Acts As A Protein Primer for Viral DNA Synthesis*, Cell, 71: 663-70 (1992)
			Yang, Y. et al., *Clearance of Adenovirus-Infected Hepatocytes by MHC Class I-Restricted CD4$^+$ CTLs In Vivo*, The Journal of Immunology, 155: 2564-70 (1995)
			Yen, T., *Posttranscriptional Regulation of Gene Expression in Hepadnaviruses*, Virology, 8: 319-26 (1998)

EXAMINER LCO	DATE CONSIDERED 11/24/04

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.